FLT3 and acute myeloid leukemia: ELN Intermediate 1–2 risk patients accounted for 47/104 (37%); 16/47 (34%) relapsed; 7/47 (15%) were transplanted in first remission (3 Flt3‐ITD positive, 2 AML with extramedullary leukemia, 2 1st induction failure); 7/47 (15%) were transplanted after relapse in 2nd CR (Table 3).